Aurobindo Pharma looks to sell cancer drugs in the US by year end

Hyderabad-based pharma major says US FDA approval likely to come after upcoming audit

Hyderabad-based Aurobindo Pharma Limited is hoping to receive three-four product approvals in the oncology space from the US Food and Drug Administration (US FDA) before March 2018.

The company's optimistic prediction about a possible good start in this high-margin product business comes just ahead of a maiden audit slated to be conducted for its oncology formulations manufacturing facility by the US drug regulator.

A research and development facility and a manufacturing plant, both dedicated to the development and production of oncology and hormonal drugs, was set up in Hyderabad by Aurobindo-controlled Eugia Pharma Specialties Ltd, a joint-venture with Sequoia-backed Celon